WHO WE ARE

We are a team of experienced leaders in medicine, research and innovation working towards improving health & wellness.

WHAT WE DO

We identify important treatment gaps for common human diseases and turn them into  opportunities to develop new ways of improving health & wellness.

WHERE WE ARE GOING

We are developing novel immune based therapies for common, chronic
inflammatory diseases.

INNOVATION

How do you progress from complex research discoveries to simple solutions that people can use? There is a need to identify common building blocks that are functional, predictable and safe.

Pemi31 Therapeutics is moving in that direction with ICASTImmune Complex Altered Signaling & Transport, a scalable platform technology with applications for many common diseases and age-related conditions.

ICAST is an important program of communication between cells. Working at the cell membrane, it can “tell” cells how to act, or block bad signals that will increase inflammation and cell death. Alternatively, ICAST can facilitate the uptake of molecules, drugs or factors that need to work inside a cell, or traverse to the other side of the cell where its target lies.

An immune complex (IC) is a combination of a protein and its antibodies. IC’s interact at the cell membrane with various receptors – sometimes simultaneously – to dial into the cells signaling or transport systems.

Pemi31 Therapeutics has discovered the therapeutic value of the IC’s formed between Heat Shock Protein 27 (HSP27) and naturally occurring antibodies to HSP27. Increasing levels of anti-HSP27 antibodies through vaccination and/or direct antibody administration has many applications, including cardiovascular / metabolic diseases, as well as other common inflammatory and degenerative processes.

To learn more about the potential of HSP27 ICAST for reducing inflammation, see our latest manuscript.

RESEARCH

The O’Brien research laboratory studies how the body develops the right responses to combat the development of hardening of the arteries (or “atherosclerosis”). In particular, we are interested in how to reduce cholesterol levels and unbridled inflammation. In pioneering studies, we discovered Heat Shock Protein 27 (HSP27) as a protein that is in part regulated by estrogens and is associated with cardiovascular health – in males and females.

The biological role of HSP27 markedly changes when this protein combines with natural anti-HSP27 antibodies to form immune complexes (ICs). Acting as a novel modulator of cell signaling and transport, HSP27 ICs constitute a platform technology called ICAST. Altering communication signals within the body, HSP27 ICAST influences the health of cells in your blood vessels, liver and potentially other target organs that maintain one’s wellness and longevity.

To learn more about HSP27 Immunotherapy for the prevention of atherosclerosis and lowering of cholesterol see our latest manuscript.

OUR TEAM

LEADERSHIP

Joe Tucker
Chief Executive Officer

Bio

Edward O’Brien
Co-Founder
Chief Scientific Officer

Bio

Michelle Gagnon
Co-Founder
Chief Operating Officer

Bio

KEY OPINION LEADERS

John Kastelein
MD, PhD

 

Bio

Kosh Ray
MD, MPhil

Bio

BLOG

Reach Us

Pemi31 Therapeutics, Inc.
Life Sciences Innovation Hub
3655 – 36 Street NW
Calgary, AB
T2L 1Y8
Canada

Leave A Message